JAK1/2 inhibitor ruxolitinib promotes the expansion and suppressive action of polymorphonuclear myeloid‐derived suppressor cells via the JAK/STAT and ROS‐MAPK/NF‐κB signalling pathways in acute graft‐versus‐host disease

OBJECTIVES: Ruxolitinib, a Janus kinase (JAK) 1/2 inhibitor, demonstrates efficacy for treating steroid‐resistant acute graft‐versus‐host disease (SR‐aGVHD) following allogeneic stem cell transplantation (allo‐HSCT). Myeloid‐derived suppressor cells (MDSCs) have a protective effect on aGVHD via supp...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Yigeng, Wang, Jiali, Jiang, Shan, Lyu, Mengnan, Zhao, Fei, Liu, Jia, Wang, Mingyang, Pei, Xiaolei, Zhai, Weihua, Feng, Xiaoming, Feng, Sizhou, Han, Mingzhe, Xu, Yuanfu, Jiang, Erlie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968240/
https://www.ncbi.nlm.nih.gov/pubmed/36855558
http://dx.doi.org/10.1002/cti2.1441

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968240/
https://www.ncbi.nlm.nih.gov/pubmed/36855558
http://dx.doi.org/10.1002/cti2.1441

Ejemplares similares